SEMAX × Limitless Life Nootropics — Lab Test, March 2026
This lab doesn't publish a public lookup, so we can't confirm the certificate against the lab's own record. The document was reviewed before publication, but it rests on our review alone.
What portal verification means →Test results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 20 mg · Lab measured 19.95 mg
100% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 5 mg on both the label figure and the measured one.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
| Report number | 1314 |
|---|---|
| Portal lookup | Lab has no portalThis laboratory publishes no public lookup, so the report cannot be confirmed independently. |
| PDF vs portal | MZ Biolabs's portal shows validity only |
| Weight | Counts as one lab test |
Independent HPLC purity analysis of N-Acetyl Semax Amidatе from Limitless Life Nootropics, performed by MZ Biolabs on March 27, 2026. Reported purity: 99.88%. Net content: 19.95 mg against 20 mg labeled (100% of label). Batch 1314. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of SEMAX from Limitless Life Nootropics
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| US116181 (#2) | 2 Oct 2025 | MZ Biolabs | 99.56% | 99% | Lab has no portal |
| 1276 (vial 2) | 8 Jul 2025 | MZ Biolabs | 98.98% | 100% | Lab has no portal |
| H1798 (US vial 2) | 2 Jun 2025 | MZ Biolabs | 98.66% | 100% | Lab has no portal |
| 117981 (US vial 2) | 24 May 2025 | MZ Biolabs | 98.66% | 100% | Lab has no portal |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion